Nanotechnology Company Guide for Biomedical Researchers
A nanotechnology company, in the biomedical context, is a supplier of engineered nanoscale materials, characterization services, or application engineering support that directly shapes whether your experiments reproduce and scale. Before you place a single order, three things must be confirmed: material characterization data (SEM/TEM images and DLS/NTA size profiles), batch traceability with a Certificate of Analysis (CoA), and access to application engineering or functionalization support. The FDA’s guidance on nanomaterial handling and disposal adds a fourth layer of institutional accountability that U.S. labs cannot skip.
- Material characterization: Demand SEM/TEM images and raw NTA or DLS files, not just summary tables.
- Batch traceability: Every lot must carry a CoA with lot number, purity metrics, and test dates.
- Application engineering: Confirm the supplier has staff who can troubleshoot dispersion, aggregation, or surface chemistry issues specific to your assay.
- Regulatory alignment: Verify the supplier provides an SDS/MSDS and can support your institution’s EH&S documentation requirements.
Pro Tip: Ask for the raw NTA data file, not just the printed report. A vendor who hesitates to share raw files is signaling limited QC depth.
Table of Contents
- What to request from a nanotechnology company before you buy
- Common nanomaterials in biomedical research and why form factor matters
- Characterization data you should require from every supplier
- Supplier capabilities that affect your research outcomes
- U.S. safety and regulatory requirements for nanomaterial handling
- Step-by-step procurement workflow and 12 questions to ask vendors
- Off-the-shelf nanoreagents versus custom synthesis: how to decide
- How to validate incoming nanomaterials before using them in experiments
- How to work with a nanotech supplier as a development partner
- Key Takeaways
- The part of supplier evaluation most labs get wrong
- Mayflowerbio supports your nanomaterial sourcing and validation workflow
- Authoritative U.S. resources for nanomaterial procurement and safety
What to request from a nanotechnology company before you buy
Procurement screening is where most labs lose time. Standardize it with this checklist before any vendor conversation goes further.
Documents to request:
- Certificate of Analysis (CoA) with lot number, purity percentage, and test methodology
- SDS/MSDS covering storage, PPE, and disposal
- NTA or DLS size-distribution report (raw data file preferred)
- SEM or TEM images with scale bars and acquisition metadata
- Endotoxin test results (LAL assay) for any bio-applicable material
- Sterility certificate where the material contacts cell cultures or in vivo models
Policies to confirm before ordering:
- Sample availability and evaluation period terms
- Minimum order quantities (MOQs) and pricing tiers by volume
- Lead times for stock versus custom synthesis
- NDA and Material Transfer Agreement (MTA) requirements
Pro Tip: Negotiate sample evaluation terms before signing an NDA. Some vendors require an NDA before releasing samples, which is reasonable, but the evaluation window and IP ownership of any data you generate should be spelled out in writing.
Common nanomaterials in biomedical research and why form factor matters
Suppliers offer nanomaterials in multiple physical forms, and the form you choose affects dispersion, sterility, and how easily the material integrates into your assay workflow.
- Carbon nanotubes (CNTs): Used in drug delivery, biosensors, and scaffold engineering. Available as raw powder, purified dispersions, or functionalized variants (carboxylated, aminated). Powders require sonication and solvent optimization; high-purity CNT demand is rising as benchtop CVD systems make in-house synthesis more accessible, though in-house production introduces amorphous carbon contamination risk without rigorous QC.
- Graphene and graphene oxide: Common in membrane research, electrochemical biosensors, and composite scaffolds. Supplied as powder, aqueous dispersion, or pre-coated substrates. Aqueous dispersions are easier to work with but have shorter shelf lives.
- Quantum dots: Used in fluorescence imaging and multiplexed detection. Require functionalization labs to ensure surface stability; bare quantum dots aggregate rapidly in biological buffers without proper capping chemistry.
- Metallic nanoparticles (gold, silver, iron oxide): Gold nanoparticles dominate in targeted delivery and SERS-based detection. Iron oxide particles are used in MRI contrast and magnetic separation. Supplied as dispersions or functionalized conjugates. Endotoxin contamination is a real risk with metallic particles produced in non-cleanroom environments.
- Polymeric nanoparticles (PLGA, PEG-based): The most clinically translatable form. Used in drug encapsulation and controlled release. Supplied pre-formed or as synthesis kits. Sterility and endotoxin testing are non-negotiable for any in vivo application.
Pro Tip: For cell-based assays, request dispersions rather than powders whenever possible. Redispersing a powder in your assay buffer introduces aggregation variables that are hard to control and harder to report.
Suppliers provide technical documentation including graphene, various carbon nanotubes, nanoparticle synthesis materials, and quantum dots to support R&D projects across these categories.
Characterization data you should require from every supplier
SEM/TEM imaging and raw dispersion data are the two most consequential documents a supplier can provide. Here is what each test tells you and when a result should trigger concern.
| Test | What It Reveals | Passing Signal | Red Flag |
|---|---|---|---|
| SEM/TEM imaging | Morphology, size, aggregation state | Uniform particles, clear scale bar, metadata intact | Blurry images, no scale bar, stock photos |
| DLS (Dynamic Light Scattering) | Hydrodynamic diameter, PDI | size matches specification | PDI > 0.3, bimodal distribution |
| NTA (Nanoparticle Tracking Analysis) | Particle concentration, size distribution | Narrow distribution, concentration within spec | Wide spread, high background noise |
| Zeta potential | Surface charge, colloidal stability | high absolute zeta potential for stable dispersion | Values near 0 mV indicate aggregation risk |
| Elemental analysis (ICP-MS/OES) | Elemental purity, metal contaminants | Matches stated composition | Unexpected peaks, low purity percentage |
| Certificate of Analysis (CoA) | Lot-specific test summary | Lot number, test dates, method references | Missing lot number, no method cited |
Minimum acceptable documentation for a critical experiment: CoA, DLS or NTA report, and at least one SEM or TEM image with metadata. For bio-applicable materials, add zeta potential and endotoxin results. Requesting raw characterization files and including acceptance criteria in your purchase order reduces disputes when a production batch differs from the sample you evaluated.
Pro Tip: Ask for the NTA metadata file, not just the exported PDF. The raw file lets your core facility re-analyze the data independently, which matters when a batch is borderline.
Supplier capabilities that affect your research outcomes
Not every nanotech firm operates the same way. The gap between a commodity distributor and a genuine research partner shows up in these specific capabilities.
- Custom functionalization: Surface chemistry modification (PEGylation, antibody conjugation, amine/carboxyl groups) requires dedicated wet-chemistry labs. Suppliers without this capability will refer you elsewhere mid-project.
- Formulation and dispersion services: Effective dispersion into biological buffers or resins often requires application engineering beyond raw material sales. Functionalization is frequently the practical bottleneck when moving nanomaterials into applied use.
- In-house characterization: Suppliers who run their own SEM/TEM, NTA, and ICP-MS can iterate faster and provide lot-specific data without outsourcing delays.
- Cleanroom or certified production: For materials destined for cell culture or in vivo work, ISO-class production environments reduce endotoxin and particulate contamination.
- Batch traceability and ISO-like quality systems: ISO 9001 or equivalent controls, lot numbers, and documented QC procedures are the baseline for reproducible science.
| Capability | Impact on Research | Risk if Absent |
|---|---|---|
| Custom functionalization | Tailored surface chemistry for your assay | Off-target binding, aggregation |
| In-house characterization | Faster iteration, lot-specific data | Delayed results, outsourced QC gaps |
| Cleanroom production | Lower endotoxin, particulate risk | Failed sterility checks, wasted experiments |
| Batch traceability | Reproducibility across experiments | Irreproducible results, audit failures |
| Application engineering | Troubleshooting support during integration | Stalled projects, no escalation path |
U.S. safety and regulatory requirements for nanomaterial handling
Lab managers in the U.S. carry specific institutional obligations when purchasing and handling nanomaterials. These are not optional.
- SDS/MSDS: Required for every nanomaterial. Confirm the SDS addresses nanoparticle-specific hazards (inhalation, dermal exposure) rather than bulk-material equivalents, which often understate risk.
- PPE and engineering controls: NIOSH recommends gloves, lab coat, and N95 or higher respiratory protection for dry nanopowder handling. Fume hoods or gloveboxes are standard for aerosolizable materials.
- Waste disposal: Nanomaterial waste typically requires segregation and disposal through your institution’s EH&S program. Confirm the supplier’s SDS includes disposal guidance consistent with EPA regulations.
- Endotoxin and sterility: Any material entering a cell culture or animal model must be tested. LAL assay results below 1 EU/mL are the standard threshold for most in vitro applications.
- IBC review: If your nanomaterial is conjugated to a biological agent (viral vector, nucleic acid, live cell), your Institutional Biosafety Committee may require a protocol review before use.
- FDA considerations: For translational or clinical-use work, FDA’s nanotechnology guidance documents apply. The agency’s biospecimen handling standards and related institutional protocols are the reference point for compliance documentation.
Nanomaterials used in drug delivery or diagnostic applications may also trigger EPA reporting requirements under TSCA if the material is novel. Confirm with your EH&S office before first use.
Step-by-step procurement workflow and 12 questions to ask vendors
Procurement workflow:
- Initial screen: Confirm the supplier provides CoA, SDS, and at least one characterization report for the specific material you need.
- NDA/MTA: Execute agreements before sharing proprietary assay details or receiving samples.
- Sample request: Order a small quantity (typically 1–5 mg or 1 mL dispersion) with full documentation.
- Technical evaluation: Run incoming QC (see Section 9) and compare results to supplier data.
- Pilot run: Use the material in a representative assay at small scale before committing to bulk.
- Document sign-off: Confirm acceptance criteria are met, file all characterization data, and issue a formal approval before bulk ordering.
12 questions to ask before engagement:
- Can you provide raw SEM/TEM image files with acquisition metadata?
- What is your NTA or DLS method, and can you share the raw data file?
- What is your sample policy, and what is the minimum order quantity for bulk?
- How do you define and document batch traceability?
- What does your CoA include, and which test methods are cited?
- Do you hold ISO 9001 or an equivalent quality certification?
- Can you perform custom functionalization, and what surface chemistries do you support?
- What is your lead time for stock materials versus custom synthesis?
- Do you provide endotoxin testing results for bio-applicable materials?
- What application engineering support is available post-purchase?
- How do you handle batch-to-batch variation, and what is your replacement policy?
- Do you require an MTA, and what IP terms apply to data generated from your materials?
Off-the-shelf nanoreagents versus custom synthesis: how to decide
The decision usually comes down to experimental sensitivity, regulatory path, and how much batch-to-batch variation your assay can tolerate.
- Choose stock reagents when: Your assay is early-stage, the material specification is standard (e.g., 20 nm citrate-capped gold nanoparticles), and speed matters more than surface-chemistry precision.
- Commission custom synthesis when: Your application requires a specific ligand, size distribution tighter than catalog spec, or a surface chemistry not available off the shelf. Custom work also makes sense when you are building toward a regulatory submission and need full synthesis documentation.
- Cost and time tradeoffs: Stock materials ship in days and cost less per unit. Custom synthesis typically adds weeks to months and carries higher per-batch costs, but the performance fit is tighter and the documentation trail is cleaner for IND or IDE filings.
Researchers should clarify early whether they need custom synthesis, specialized dispersion, or high-purity stock materials, since the supplier type changes contract terms, lead times, and QC expectations entirely.
Pro Tip: Run a small pilot with a stock reagent first. If it fails your functional assay, you have a documented baseline that justifies the custom synthesis budget to your PI or procurement committee.
How to validate incoming nanomaterials before using them in experiments
Never assume the production batch matches the sample. Run these checks on arrival.
- Visual inspection: Check for color change, visible aggregates, or phase separation. Any of these warrants a hold.
- Re-run DLS or NTA: Compare hydrodynamic diameter and PDI to the supplier’s CoA. A shift of more than 15% in mean size or PDI above 0.3 is a rejection trigger.
- Zeta potential spot-check: Confirm surface charge is within ±5 mV of the supplier’s reported value.
- TEM spot-check: Send a sample to your core facility if morphology is critical. Even a single-grid check catches gross aggregation or contamination.
- Endotoxin assay: Run a LAL assay on any material entering cell culture. Do not skip this step based on supplier certification alone.
- Functional assay: Run the material in a simplified version of your intended assay (e.g., uptake in a cell line, binding to a target) before committing to a full experiment.
Acceptance criteria to document: Size within ±15% of spec, PDI < 0.25, zeta potential within ±5 mV, endotoxin < 1 EU/mL, and functional assay result within pre-defined performance bounds. File all results with the lot number and date received. Mayflowerbio’s NTA size profiling service can support independent verification when your lab lacks in-house NTA capability.
How to work with a nanotech supplier as a development partner
The suppliers who add the most value are not the ones with the largest catalog. They are the ones who show up at the technical scoping call with questions about your assay, not just your order quantity.
- Early technical scoping: Share your assay format, buffer conditions, and downstream processing steps before finalizing material specs. A supplier with application engineering experience will flag compatibility issues before you waste a batch.
- Shared acceptance criteria: Put pass/fail thresholds in writing before the first shipment. This protects both sides and eliminates ambiguity when a borderline batch arrives.
- Scheduled data reviews: Build quarterly or milestone-based data reviews into the supplier agreement. Early-stage collaboration where suppliers participate as development partners consistently produces better outcomes than transactional purchasing.
- Pilot milestones in contracts: For custom functionalization projects, include scheduled pilot milestones with defined deliverables. Iterative co-design between your lab and the supplier is how stable dispersions and printable inks actually get built.
Pro Tip: Include a clause in your supply agreement that specifies the supplier’s obligation to provide application engineering hours per quarter. Without it, technical support becomes informal and inconsistent as the relationship matures.
Key Takeaways
Choosing the right nanotech supplier requires verifying material characterization data, batch traceability, and application engineering support before any bulk commitment.
| Point | Details |
|---|---|
| Demand raw characterization files | Request SEM/TEM image files and NTA raw data, not just printed summary reports. |
| Confirm batch traceability upfront | Every lot must carry a CoA with lot number, purity percentage, and cited test methods. |
| Run incoming QC on every batch | Re-run DLS or NTA on arrival and compare to supplier data before using materials in experiments. |
| Match supplier type to project stage | Use stock reagents for early-stage work; commission custom synthesis when regulatory documentation or tight specs are required. |
| Mayflowerbio for validation support | Mayflowerbio’s NTA size profiling service and bioassay product lines support independent incoming QC and functional validation workflows. |
The part of supplier evaluation most labs get wrong
The procurement checklist in this article covers the technical basics well. What it cannot fully capture is the organizational signal a supplier sends in the first two conversations.
Most labs evaluate vendors on price, lead time, and catalog breadth. Those matter. But the variable that actually predicts whether a nanomaterial project succeeds or stalls is whether the supplier’s technical team understands your application well enough to push back on your spec. A vendor who accepts every order without comment is a distributor. A vendor who asks why you chose a 50 nm particle over a 20 nm particle for your uptake assay, and has a reasoned opinion about it, is a partner.
The supplier evaluation criteria that matter most in practice are documentation depth, application engineering availability, and willingness to share raw data. Those three things, more than any catalog feature, predict whether a supplier relationship survives the first batch discrepancy.
Mayflowerbio supports your nanomaterial sourcing and validation workflow
Sourcing nanomaterials is only half the challenge. Validating them against your specific assay conditions is where most procurement workflows break down, and where Mayflowerbio adds direct value.
Mayflowerbio offers NTA size profiling for independent particle characterization, a broad catalog of bioassay products for functional validation, and reagent lines spanning antibodies, PCR reagents, and cell biology tools that integrate directly into nanomaterial QC workflows. For labs building out a supplier approval process, Mayflowerbio’s U.S.-based technical team can support documentation review and incoming QC protocol design. Browse the full product catalog or contact the team directly at mayflowerbio.com to discuss your sourcing and validation needs.
Authoritative U.S. resources for nanomaterial procurement and safety
- NIOSH Nanotechnology Research: The National Institute for Occupational Safety and Health publishes guidance on engineering controls, PPE, and exposure limits for engineered nanomaterials. Essential reading for EH&S documentation.
- FDA Nanotechnology Guidance Documents: The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) publish guidance relevant to nanomaterial use in drug delivery and diagnostics. Required reference for any translational work.
- EPA TSCA Nanomaterial Reporting: The Environmental Protection Agency’s TSCA Section 8(a) rule requires reporting for certain nanomaterials. Confirm applicability with your EH&S office before first use of a novel material.
- NIH Institutional Biosafety Committee (IBC) Resources: NIH’s Office of Science Policy provides IBC guidance relevant to nanomaterials conjugated to biological agents. Check the OSP website for current protocol templates.
- NIST Center for Nanoscale Science and Technology: NIST provides reference materials and measurement standards for nanoparticle characterization, including certified reference standards for DLS and NTA calibration.
- University Core Facilities (TEM/SEM, NTA): Most R1 institutions operate electron microscopy and nanoparticle characterization core facilities. These are the fastest path to independent verification of supplier data without capital equipment investment.
